Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer

Hatanaka, Hiroyuki; Abe, Yoshiyuki; Kamiya, Takashi; Morino, F; Nagata, Junko; Tokunaga, Tetsuji; Oshika, Y; Suemizu, Hiroshi; Kijima, Hiroshi; Tsuchida, Takashi; Yamazaki, Hitoshi; Inoué, Hiroshi; Nakamura, Masato; Ueyama, Yoshito

doi:10.1023/a:1008375208574

Cited by 86 publications

(67 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Il-10 and Nonsmall Cell Lung Cancer E Zeni Et Alcontrasting

confidence: 99%

“…These findings are in contrast with a previous report of HATANAKA et al [7], who suggested that IL-10 expression by the tumour is an indicator of poor prognosis in NSCLC patients. In the present study, IL-10 expression was analysed at the protein level whereas the mRNA level was analysed by HATANAKA et al [7]. The difference between the present results and those by HATANAKA et al [7] are probably due to the fact that the mRNA measurements were performed globally on tissues including tumour cells, stromal cells and TAMs.…”

Section: Il-10 and Nonsmall Cell Lung Cancer E Zeni Et Alcontrasting

confidence: 99%

“…In the present study, IL-10 expression was analysed at the protein level whereas the mRNA level was analysed by HATANAKA et al [7]. The difference between the present results and those by HATANAKA et al [7] are probably due to the fact that the mRNA measurements were performed globally on tissues including tumour cells, stromal cells and TAMs. Indeed, by performing an immunohistochemical analysis in the present study, it was possible to identify TAMs as the cells that contribute to the expression that correlates with higher tumour stage, progression and survival.…”

Section: Il-10 and Nonsmall Cell Lung Cancer E Zeni Et Alcontrasting

confidence: 57%

“…IL-10 is produced by a variety of tumour cells, and its immunomodulatory effects have yielded controversial results as regards tumour growth and progression. NSCLC patients with IL-10 expression within their tumour cells showed a poorer prognosis than those without IL-10 expression [7]. In contrast, the lack of IL-10 expression in patients with stage I NSCLC was associated with a worse outcome [8].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer

Zeni¹,

L²,

Miotto³

et al. 2007

European Respiratory Journal

View full text Add to dashboard Cite

Interleukin (IL)-10 is expressed in many solid tumours and plays an ambiguous role in controlling cancer growth and metastasis. In order to determine whether IL-10 is involved in tumour progression and prognosis in nonsmall cell lung cancer (NSCLC), IL-10 expression in tumour cells and tumour-associated macrophages (TAMs) and its associations, if any, with clinicopathological features were investigated.Paraffin-embedded sections of surgical specimens obtained from 50 patients who had undergone surgery for NSCLC were immunostained with an antibody directed against IL-10. TAMs and tumour cells positive for IL-10 were subsequently quantified.IL-10-positive TAM percentage was higher in patients with stage II, III and IV NSCLC, and in those with lymph node metastases compared with patients with stage I NSCLC. High IL-10 expression by TAMs was a significant independent predictor of advanced tumour stage, and thus was associated with worse overall survival. Conversely, IL-10 expression by tumour cells did not differ between stages II, III and IV and stage I NSCLC.In conclusion, interleukin-10 expression by tumour-associated macrophages, but not by tumour cells, may play a role in the progression and prognosis of nonsmall cell lung cancer. These results may be useful in the development of novel approaches for anticancer treatments.

show abstract

Section: Il-10 and Nonsmall Cell Lung Cancer E Zeni Et Alcontrasting

confidence: 99%

Section: Il-10 and Nonsmall Cell Lung Cancer E Zeni Et Alcontrasting

confidence: 99%

Section: Il-10 and Nonsmall Cell Lung Cancer E Zeni Et Alcontrasting

confidence: 57%

mentioning

confidence: 99%

See 2 more Smart Citations

Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer

Zeni¹,

L²,

Miotto³

et al. 2007

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…2 In fact, we previously reported that TGF-b1 was expressed in gastric cancer tissues and correlated with poor prognosis. 16 With regard to IL-10, recent studies demonstrated that IL-10 was also expressed in some cancers, including lung cancer 17 and melanoma. 9 Moreover, it has been reported that IL-10 expression significantly correlated with poor prognosis in non-small cell lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Interleukin‐10 expression significantly correlates with minor CD8⁺ T‐cell infiltration and high microvessel density in patients with gastric cancer

Sakamoto

Saito

Tatebe

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

We aimed to investigate the relationships between interleukin-10 (IL-10) expression and both the clinicopathological findings and prognoses in patients with gastric cancer and to compare IL-10 expression with microvessel (MV) density and CD81 T lymphocyte infiltration to evaluate its effects on angiogenesis and immune responses in gastric cancer. IL-10 expression was determined in gastric cancer patients by reverse transcription-polymerase chain reaction (RT-PCR) or immunohistochemical procedures. Two of 7 normal gastric tissues showed IL-10 mRNA expression, while its expressions were confirmed in all advanced gastric carcinoma tissues examined (n 5 11) by RT-PCR. Immunohistochemical staining demonstrated that IL-10 expression was detected in 52 (47.7%) of 109 cases. There was a close correlation between IL-10 expression and MV density. IL-10 expression inversely correlated with CD81 T-lymphocyte infiltration. The prognoses of patients whose tumors expressed IL-10 were significantly worse than those of patients whose tumors did not express IL-10. Multivariate analysis indicated IL-10 expression was an independent prognostic factor. IL-10 might be associated with tumor progression by stimulating angiogenesis and suppressing immune responses in gastric cancer. ' 2005 Wiley-Liss, Inc.

show abstract

Cytokines in pancreatic carcinoma

Ebrahimi

Tucker

et al. 2004

Cancer

266

102

View full text Add to dashboard Cite

BACKGROUND.Cytokines have been implicated in diverse processes that are relevant to pancreatic carcinoma, including cachexia, asthenia, and tumor growth. The objective of this study was to examine the association between serum levels of proinflammatory and antiinflammatory or angiogenic cytokines and the outcomes of patients with pancreatic carcinoma. METHODS.Serum cytokine levels were measured by enzyme-linked immunosorbent assay from 51 patients with pancreatic carcinoma and from 48 -62 healthy volunteers. Cytokine levels were compared with disease manifestations and overall survival. RESULTS.Circulating levels of vascular endothelial growth factor, tumor necrosis factor alpha, interleukin-1␣ (IL-1␣), and IL-1␤ were not elevated significantly in patients with pancreatic carcinoma, but levels of IL-6, IL-8, IL-10, and IL-1 receptor antagonist (IL-1RA) were elevated significantly (P Ͻ 0.05). Cytokine levels were dichotomized based on an analysis of null Martingale residuals. Patients who had IL-6 levels Ͼ 5.2 pg/mL or IL-10 levels Ͼ 9.8 pg/mL had significantly worse survival compared with patients who had lower IL-6 or IL-10 levels (P Ͻ 0.05). IL-8 levels were not associated with survival differences. Patients who had IL-1RA levels Ͻ 159 pg/mL had significantly worse survival compared with patients who had higher IL-1RA levels (P Ͻ 0.05). Higher IL-6, IL-10, and IL-8 levels were associated with poor performance status and/or weight loss. In multivariate analysis, only T 4 tumors and high IL-6 levels were selected as independent prognostic factors for poor survival. CONCLUSIONS.Circulating levels of several cytokines were high in patients with pancreatic carcinoma, and their association with weight loss and poor performance status suggested that they may be involved in these disease manifestations.

show abstract

Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer

Abstract: These results suggested that the cytoplasmic IL-10 correlated to clinical prognosis, and that IL-10 expression is a prognostic factor for NSCLC.

Cited by 86 publications

References 16 publications

Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer

Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer

Interleukin‐10 expression significantly correlates with minor CD8⁺ T‐cell infiltration and high microvessel density in patients with gastric cancer

Cytokines in pancreatic carcinoma

Contact Info

Product

Resources

About

Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer

Abstract: These results suggested that the cytoplasmic IL-10 correlated to clinical prognosis, and that IL-10 expression is a prognostic factor for NSCLC.

Cited by 86 publications

References 16 publications

Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer

Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer

Interleukin‐10 expression significantly correlates with minor CD8+ T‐cell infiltration and high microvessel density in patients with gastric cancer

Cytokines in pancreatic carcinoma

Contact Info

Product

Resources

About

Interleukin‐10 expression significantly correlates with minor CD8⁺ T‐cell infiltration and high microvessel density in patients with gastric cancer